Biochemical Evaluation of the Response to Non-Surgical Treatment of Peri-Implant Mucositis in Individuals with Different Periodontal Conditions

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20251229012

Enrollment

Registered

2025-12-29

Start date

2025-11-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

This study investigates gingivitis, peri-implant mucositis, peri-implant health, and periodontal health in systemically healthy individuals. Periodontal health, Gingivitis, Peri-implant mucositis, Peri-implant health, Dental plaque, Inflammation, Biomarkers, IL-1b, IL-6, MCP-1, MIP-1a, Non-surgical periodontal therapy

Interventions

Systemically healthy individuals presenting with generalized gingivitis and at least one implant diagnosed with peri-implant mucositis. Diagnosis based on clinical parameters such as bleeding on probi

Diagnostic,Diagnostic,Diagnostic

Individuals with peri-implant mucositis and dental plaque-induced gingivitis,Periodontally healthy individuals with peri-implant mucositis,Periodontally healthy individuals with peri-implant mucositis

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1-Presence of at least one dental implant with a fixed prosthetic restoration in function for at least 1 year 2-No systemic diseases or conditions affecting periodontal or peri-implant tissues (e.g., diabetes, cardiovascular disease) and no relevant medication use 3-No periodontal treatment received in the past 6 months 4-Age between 18 and 65 years 5-Non-smoker 6-Willingness to participate and provide informed consent

Exclusion criteria

Exclusion criteria: 1-Presence of systemic diseases or conditions 2-Use of antibiotics or anti-inflammatory drugs within the past 3 months 3-Use of medications affecting gingival health (e.g., phenytoin, calcium channel blockers, cyclosporine, anticoagulants) 4-Pregnancy or breastfeeding 5-Presence of periodontitis 6-Smoking or tobacco use 7-Malpositioned implants 8-Implants with excessive prosthetic contour preventing peri-implant pocket measurement 9-Individuals with full-mouth implants or overdenture implants

Design outcomes

Primary

Measure	Time frame
Gingival inflammation Baseline, 6 weeks, 12 weeks Gingival Index (GI) scoring,IL-1B in saliva Baseline, 6 weeks, 12 weeks ELISA assay,IL-1B in gingival crevicular fluid (GCF) / peri-implant sulcus fluid (PISF) Baseline, 6 weeks, 12 weeks ELISA assay,Peri-implant inflammation Baseline, 6 weeks, 12 weeks Gingival Index / Peri-implant Index,Probing depth (teeth) Baseline, 6 weeks, 12 weeks Periodontal probe (mm),Probing depth (implant) Baseline, 6 weeks, 12 weeks Periodontal probe (mm)	—

Measure

Time frame

Gingival inflammation Baseline, 6 weeks, 12 weeks Gingival Index (GI) scoring,IL-1B in saliva Baseline, 6 weeks, 12 weeks ELISA assay,IL-1B in gingival crevicular fluid (GCF) / peri-implant sulcus fluid (PISF) Baseline, 6 weeks, 12 weeks ELISA assay,Peri-implant inflammation Baseline, 6 weeks, 12 weeks Gingival Index / Peri-implant Index,Probing depth (teeth) Baseline, 6 weeks, 12 weeks Periodontal probe (mm),Probing depth (implant) Baseline, 6 weeks, 12 weeks Periodontal probe (mm)

—

Secondary

Measure	Time frame
IL-6 in saliva Baseline, 6 weeks, 12 weeks ELISA assay,IL-6 in GCF / PISF Baseline, 6 weeks, 12 weeks ELISA assay,MCP-1 in saliva Baseline, 6 weeks, 12 weeks ELISA assay,MCP-1 in GCF / PISF Baseline, 6 weeks, 12 weeks ELISA assay,MIP-1a in saliva Baseline, 6 weeks, 12 weeks ELISA assay,MIP-1a in GCF / PISF Baseline, 6 weeks, 12 weeks ELISA assay	—

Countries

Turkey

Contacts

Public ContactBurcu Karaduman

Biruni University Faculty of Dentistry

bkaraduman@biruni.edu.tr905323763366

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026